Last reviewed · How we verify
Placebo Peel
Placebo Peel is a Small molecule drug developed by ZARS Pharma Inc.. It is currently in Phase 3 development. Also known as: Placebo.
Placebo Peel does not have a known mechanism of action.
Placebo Peel is a study intervention that has been used in clinical trials to evaluate its effects on various conditions, including overweight, obesity, periodontitis, and gingivitis. The exact mechanism of Placebo Peel is unknown, as per the information available on ChEMBL.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Placebo Peel |
|---|---|
| Also known as | Placebo |
| Sponsor | ZARS Pharma Inc. |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
As a placebo, it is designed to mimic the appearance and feel of an actual medication without any active therapeutic effect.
Approved indications
Common side effects
Key clinical trials
- Investigation of the NMDA Antagonist Ketamine as a Treatment for Tinnitus (PHASE2)
- Gastric Emptying With Trou Normand (NA)
- ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response (PHASE2)
- Lavender Aromatherapy for Preoperative Anxiety in Melanoma and Epithelioma Patients (NA)
- Evaluation Of The Efficacy Of Subgingival Application Of Lovastatin Gel As An Adjunct To Non-Surgical Treatment Of Periodontitis In Generally Healthy Smokers And Non-Smokers Patients in Central Europe. (NA)
- Evaluation of Locally Applied Ferulic Acid as Adjunct to Mechanical Debridement in Treatment of Periodontitis (PHASE1, PHASE2)
- 6-year Outcomes in Children After Nifedipine vs Placebo for Preterm Prelabor Rupture of Membranes at 22-33 Weeks
- Oral Health Outcomes With Amphion Mouthwash as an Adjunct to Non-Surgical Periodontal Therapy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo Peel CI brief — competitive landscape report
- Placebo Peel updates RSS · CI watch RSS
- ZARS Pharma Inc. portfolio CI
Frequently asked questions about Placebo Peel
What is Placebo Peel?
How does Placebo Peel work?
Who makes Placebo Peel?
Is Placebo Peel also known as anything else?
What development phase is Placebo Peel in?
Related
- Manufacturer: ZARS Pharma Inc. — full pipeline
- Also known as: Placebo
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing